Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ)
CNY 18.9
(-0.37%)
CNY 18.9
(-0.37%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 590.01 Million CNY | -8.03% |
| 2022 | 641.53 Million CNY | 73.14% |
| 2021 | 370.53 Million CNY | 2.35% |
| 2020 | 362.02 Million CNY | 20.75% |
| 2019 | 299.81 Million CNY | 13.01% |
| 2018 | 265.3 Million CNY | 5.64% |
| 2017 | 251.13 Million CNY | 0.57% |
| 2016 | 249.7 Million CNY | 0.0% |
| 2014 | 260.1 Million CNY | -3.43% |
| 2013 | 269.34 Million CNY | 24.31% |
| 2012 | 216.67 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 585.54 Million CNY | -0.76% |
| 2024 Q2 | 586.03 Million CNY | 0.08% |
| 2024 Q3 | 630.16 Million CNY | 7.53% |
| 2023 Q3 | 466.3 Million CNY | 17.32% |
| 2023 Q4 | 590.01 Million CNY | 26.53% |
| 2023 FY | 590.01 Million CNY | -8.03% |
| 2023 Q1 | 753.23 Million CNY | 17.41% |
| 2023 Q2 | 397.46 Million CNY | -47.23% |
| 2022 Q4 | 641.53 Million CNY | -9.83% |
| 2022 FY | 641.53 Million CNY | 73.14% |
| 2022 Q3 | 711.47 Million CNY | 13.84% |
| 2022 Q2 | 624.98 Million CNY | 13.86% |
| 2022 Q1 | 548.93 Million CNY | 48.15% |
| 2021 Q2 | 402.53 Million CNY | -9.29% |
| 2021 Q3 | 517.17 Million CNY | 28.48% |
| 2021 Q1 | 443.77 Million CNY | 22.58% |
| 2021 FY | 370.53 Million CNY | 2.35% |
| 2021 Q4 | 370.53 Million CNY | -28.35% |
| 2020 Q3 | 417.95 Million CNY | 32.43% |
| 2020 FY | 362.02 Million CNY | 20.75% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 Q4 | 362.02 Million CNY | -13.38% |
| 2020 Q2 | 315.59 Million CNY | 0.0% |
| 2019 Q2 | 365.43 Million CNY | 4.92% |
| 2019 FY | 299.81 Million CNY | 13.01% |
| 2019 Q4 | 299.81 Million CNY | 6.54% |
| 2019 Q3 | 281.41 Million CNY | -22.99% |
| 2019 Q1 | 348.31 Million CNY | 0.0% |
| 2018 FY | 265.3 Million CNY | 5.64% |
| 2017 FY | 251.13 Million CNY | 0.57% |
| 2016 FY | 249.7 Million CNY | 0.0% |
| 2014 FY | 260.1 Million CNY | -3.43% |
| 2013 FY | 269.34 Million CNY | 24.31% |
| 2012 FY | 216.67 Million CNY | 0.0% |